Inactive Instrument

Press Releases Stemline Therapeutics, Inc.

Equities

US85858C1071

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	20-12-17	AQ
STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-06-10	AQ
STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	20-05-11	AQ
Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	20-05-05	AQ
STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-05-04	AQ
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million	20-05-04	GL
STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	20-03-16	AQ
Stemline Therapeutics : Reports Fourth Quarter 2019 Financial Results	20-03-16	AQ
Stemline Therapeutics: 4Q Earnings Snapshot	20-03-13	AQ
Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results	20-03-13	GL
Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020	20-03-11	GL
Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference	20-02-26	GL
Stemline Therapeutics : Announces Preliminary 2019 Net Revenues for ELZONRIS and Highlights Commercial and Clinical Growth Drivers	20-01-14	AQ
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers	20-01-13	GL
Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference	20-01-08	GL
Stemline Therapeutics : Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis and Multiple Myeloma	19-12-11	AQ
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting	19-12-10	GL
Stemline Therapeutics : Names Robert M. Francomano Chief Commercial Officer	19-12-09	AQ
Stemline Therapeutics : Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting	19-12-09	AQ
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer	19-12-06	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Stemline Therapeutics, Inc.

Equities

US85858C1071

Press Releases

Filters